General Information of Drug (ID: DM1PQJO)

Drug Name
Enapotamab vedotin
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB16156
TTD ID
DI0ZA3

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase UFO (AXL) TTZPY6J UFO_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase UFO (AXL) DTT AXL 1.13E-65 -0.53 -2.04
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02988817) Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors. U.S. National Institutes of Health.
2 Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.